Stem cell treatments and clinical trials
One day, stem cell treatments could…
Repair damaged tissue
Regrow and replace worn out organs
Cure life-threatening diseases
Cord blood stem cells are a precious resource that have been saving lives for more than three decades. Since 1988, there have been more than 1 million stem cell treatments worldwide6 and umbilical cord blood stem cells are the recognised therapy for over 80 diseases.12 These include various cancers, blood and immune disorders.
Stem cells are also considered to be a cornerstone of a relatively new area of science known as regenerative medicine. In the near future it is likely that stem cell treatments will provide cures for common and often life-threatening conditions such as heart disease, Alzheimer’s and diabetes. Within your child’s lifetime their cord blood may even be used to repair spinal damage, print kidneys or grow a new heart.
Because haematopoietic stem cells (HSCs) can transform into any type of blood cell, they are currently being used in stem cell treatments for various blood cancers and disorders. This includes leukaemia, lymphoma and myeloma.
This groundbreaking medical field uses stem cells to treat diseases and repair or replace damaged tissues and organs. This exciting area of medicine promises some extraordinary medical possibilities within your child’s lifetime, with mesenchymal stem cells (MSCs) considered to be an extremely important part of future developments.
You only have one chance to secure all of this potential for your child – the day they are born…
Stem cell treatments today
Umbilical cord blood contains millions of haematopoietic stem cells (HSCs). These are the stem cells that can transform into any type of blood cell. Because of this ability, cord blood can be used to rebuild the immune system of patients whose white blood cells are decimated by aggressive cancer therapies and those who suffer from genetic conditions of the haematopoietic system.
HSCs are the primary cell type used for today’s stem cell treatments, and have been proven to be safe and effective in thousands of treatments and trials.
Stem cell treatments in the future
Regenerative medicine is a relatively new branch of therapy that deals with replacing, creating and regenerating human cells, tissue and organs. Regenerative therapies aim to restore normal function for those afflicted with injury or disease or introduce normal function for the first time for conditions suffered from birth.
Stem cells are central to the development of regenerative medicine and cord blood stem cells in particular show a great deal of promise due to their pure and plastic nature.
Stem cell researchers are currently conducting more than 6,500 clinical trials to investigate the application of stem cell treatments for hundreds of different conditions, many of which, up until this point, have been incurable. You may have heard news stories about stem cells helping a paralysed man to walk again or restoring sight to sufferers of blindness.
Therapies like this used to be the stuff of science fiction but regenerative medicine is helping scientists to make it reality. The growth of this new area of stem cell therapy is demonstrated by the fact that 48% of cord blood bank releases have been for regenerative treatments. It is often for its regenerative potential that so many families choose to store their children’s cord blood.
The routine use of cord blood stem cells in regenerative therapies is not as far off as you might think…
Cerebral palsy is a term that describes a variety of brain conditions that emerge in early childhood and affect coordination and movement. It is usually caused by a trauma to the brain suffered in the womb or during birth. In the UK, 1 in 400 children will suffer from cerebral palsy and to date, whilst palliative therapies exist, there is no treatment for the condition itself.
However, cord blood could provide the solution. In 2012, Dr Joanne Kurtzburg began enrolling cerebral palsy sufferers whose parents banked their cord blood at birth on a pioneering clinical trial investigating the use of stem cells to treat the condition.
Whilst it is too early for final results, initial reports have been very positive with 70% of participants demonstrating improved brain development and motor skill. The success of this trial is highlighted by the continued development of the Duke University cord blood project. In June 2014, Dr Kurtzburg and her team were granted $15 million to investigate the application of cord blood stem cell treatments for other illnesses including stroke, autism and other brain disorders.
This money is the first instalment in the funding of this $41 million, 5-year project. The results of this program will be very exciting and such pioneering work would not have been possible without the thousands of parents who chose to bank their children’s precious cord blood at birth.
Your child’s key to the future…
Your baby’s cord blood could be their key to all of these stem cell treatments. Whilst there are some conditions – such as leukaemia – where a sibling’s or donor cells may be preferable, in many therapies, especially regenerative treatments, having access to their own stem cells is far better. All donor samples are matched to the recipient but there is a risk that when they are introduced into the human body during treatment they will be rejected. This is called graft-versus-host disease and can cause extremely serious side effects, including death.
Storing your baby’s own stem cells ensures that they have their own perfect genetic match ready and waiting – one that could provide access to all these stem cell treatments and more… one that will never be rejected.
About cord blood clinical trials…
What is a clinical trial?
A clinical trial is a research study that tests a health-related treatment or intervention on groups of people, in an attempt to evaluate the outcome on their health.
They can look at risks, causes, prevention, diagnosis, treatments or symptom control.
What are the phases of a clinical trial?
Generally, there are three phases of a clinical trial before doctors can accept and use a new treatment.
Phase 1 – usually a small trial with only a few patients, which aims to access safety, refine the treatment process and measure the results. This is an early stage, where scientists measure the effects and side effects of their methods.
Phase 2 – the second stage of a clinical trial aims to determine if a new treatment is worth expanding into a phase 3 trial. More patients are enlisted to measure the efficacy of the treatment. It is usually a larger scale trial that the Phase 1.
Phase 3 – the third stage trial compares the current or standard treatment for a condition with the new method. By doing so, researchers can ascertain efficacy as well as potential improvement over existing techniques.
Cells4Life offers special +PROTECTExtra insurance, so that your child can access a clinical trial in the event of being diagnosed with cerebral palsy in the first three years of their life.
What conditions can be treated with umbilical cord blood?
Currently, more than 80 conditions can be treated with stem cells, including leukaemia and multiple myeloma. This number continues to rise and in future, will include other conditions such as cerebral palsy, autism and diabetes.
Latest Stem Cell News
To kick off the new year, we’ve taken a look back at some of the many cord blood developments of 2018 and a look forward to what 2019 could hold. Here is our stem cell timeline... Cerebral palsy and autism release Cells4Life released our 10th sample to...read more
A new NHS trial has been established to investigate the viability of lung cancer stem cell therapy as a replacement for chemotherapy. The news comes after doctors at University College London (UCL) proved that mesenchymal stem cells, which are found in umbilical cord...read more
Cord blood stem cells could cure blood cancer and HIV at the same time, thanks to a new clinical trial run by the Fred Hutchinson Cancer Research Centre in Seattle, Washington. Scientists at ‘Hutch’ announced their newest project last week, which will see...read more